Trial Profile
A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Sapacitabine (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Apr 2023 Status changed from active, no longer recruiting to discontinued, according to Results presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 19 Apr 2023 Results presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 12 Jan 2022 Status changed from recruiting to active, no longer recruiting.